Skip to main content
In Vivo Preclinical Imaging

IVISense Edema Fluorescent Probe

Section
IVISense Fluorescent Imaging Probes - Vascular
In Vivo Imaging
IVISbrite Bacterial Cell Lines
IVISbrite Lentiviral Particles
IVISbrite Bioluminescent Substrates
IVISense Fluorescent Imaging Probes - Targeted
IVISbrite Tumor Cell Lines
IVISense Fluorescent Imaging Probes - Vascular
IVISense Fluorescent Imaging Probes - Activatable
IVISense Fluorescent Dyes
Applications
Best Practices
Sub Section
IVISense Edema Fluorescent Probe
IVISense Vascular NP Fluorescent Probes
IVISense Vascular Fluorescent Probes
IVISense GFR Fluorescent Probe
IVISense Gastrointestinal Fluorescent Probe
IVISense Acute Vascular Fluorescent Probes
IVISense Edema Fluorescent Probe

IVISense™Edema 680 (formerly Superhance) is a small molecule fluorescent in vivo blood pool imaging probe. IVISense Edema 680 enables imaging of circulation, blood vessels, vasculature, vascular leak, including that associated with early oncologic and opthalmologic lesions.

Products and catalog numbers

 

Product Catalog Number Ex/Em wavelength (nm) Molecular weight (g/mol) Validated Experiments Applications
IVISense Edema 680 NEV10116 675/692 ~ 1540 In vivo Vascular
Cancer/Tumor 

 

Using IVISense Edema 680 probe for in vivo studies

The generally recommended procedure for in vivo imaging with IVISense Edema 680 is administration via tail vein injection and imaging 0.5 – 24 hours post-injection.

  • For Acute Edema, we recommend imaging 3 hours post injection.
  • For IVM: 5-15 min post injection

 

Product Route of Injection Mouse Dose (25 g) Rat Dose (250 g) Blood t 1/2 Tissue t 1/2 Optimal imaging time Optimal Re-injection Time (complete clearance) Route of Metabolism/ background tissue FMT& IVIS settings
IVISense Edema 680 IV 4 nmol (150 uL) 12-40 nmol 1.5 h 5 h 3 h (1-3 h) 96 h Bladder FMT 680/700
IVIS 675/720 

To determine the optimal imaging timepoint relative to probe injection, we imaged 4T1 tumor-bearing mice at different times post-IVISense Edema 680 injection (Figure 1). Whole body images at 3 h post-injection (Figure 1A) reveal signal throughout the body (including bladder, intestines, liver, and heart) as well as in the tumor periphery.

edema.png

Figure 1. Imaging tumors. FMT and planar images show the patterns of fluorescence that occur in animals bearing tumor masses on the upper mammary fat pads. A) Whole body signal using fluorescence tomography imaging. B) Tomography imaging showing only tumor region fluorescence over time. Inset panels represent surface fluorescence detected by planar imaging.

Application notes and posters

Application note: Comparison of Revvity Vascular Pre-clinical Fluorescent Imaging Probes in Oncology and Inflammation Research

 

For research use only. Not for use in diagnostic procedures.

The information provided above is solely for informational and research purposes only. The information does not constitute medical advice and must not be used or interpreted as such. Consult a qualified veterinarian or researcher for specific guidance on injection techniques or other animal procedures. Revvity assumes no liability or responsibility for any injuries, losses, or damages resulting from the use or misuse of the provided information. The information is provided on an "as is" basis without warranties of any kind. Users are solely responsible for complying with all relevant laws, regulations, and institutional animal care and use committee (IACUC) guidelines in their use of the information provided.

ON THIS PAGE